The Company, along with its Research and Development Teams, were shortlisted for continuing its mission of turning artificial intelligence into a force for human intelligence
King of Prussia, PA – February 18th, 2025: CluePoints
provider of leading statistical and AI-driven software solutions, has been shortlisted for “Team Excellence in the Management of Clinical Data” at the 2025 ACDM Awards.
CluePoints, along with its Research and Development Teams, released three new products in 2024, aiming to transform clinical trial review and leveraging industry-leading software to enhance the interrogation, analysis and presentation of data.
Site Profile & Oversight Tool (SPOT) delivers adaptive site monitoring, enabling teams to swiftly pinpoint anomalies and translate insights into strategies and actions. Allowing sponsors and CROs to improve their ability to evaluate the performance of clinical trial sites and adjust site visit plans more effectively and efficiently while accurately balancing risk and resource workload.
The Intelligent Medical Coding (IMC) solution harnesses advanced deep learning technology to enhance the accuracy and efficiency of coding in clinical trials. It seamlessly integrates with existing systems to offer precise, AI-generated coding suggestions, drastically reducing the need for manual dictionary searches and removing the burden of synonym management, freeing valuable resources and ensuring uniformity across all coded data.
CluePoints’ Medical Safety Review (MSR) tool simplifies and streamlines the medical analysis of study data through user-friendly dashboards, data manipulation and cleaning, query management and full transparency over the data history. The tool improves the efficiency of time to set up medical review visualizations and performing medical reviews, improving efficiency and communication in medical oversight and elevating patient safety.
Andy Cooper, CEO at CluePoints, commented: “We are honored to have our Research and Development Teams and their tireless hard work be recognized by the ACDM Awards alongside other industry leaders. Being shortlisted for this accolade is testament to the innovations being produced by CluePoints as we continue to turn artificial intelligence into human intelligence. The introduction of SPOT, IMC and MSR to our evolving product portfolio is enabling our customers to run smarter clinical trials, helping bring new therapies to market faster for the benefit of patients globally.”
The winners will be announced March 3rd at a ceremony during the 2025 ACDM Annual Conference at the Clarion Congress Hotel, Prague.
-END-
About CluePoints
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. We are leveraging the potential of Artificial Intelligence using Advanced Statistics and Machine Learning to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation, you now have everything you need to adhere with global regulatory guidance. The result is positive clinical development outcomes, increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.
Media Contact
Jodie Dixon – Discovery PR, on behalf of CluePoints
Email: [email protected]
Mobile: +44 (0)7507 727721
Office: +44 (0) 1606 889 194
